Dr. Chet Leach is a Scientific Advisor at the Lovelace Respiratory Research Institute and a private consultant for over 35 pharmaceutical and biotech companies in the area of pulmonary drug development. He also sits on numerous scientific advisory boards.
Dr. Leach has spent his career in lung research, primarily in pulmonary drug development and delivery in the pharmaceutical and biotechnology industries. He has been responsible for the nonclinical development of small molecules, proteins, and peptides in therapeutic areas such as asthma, COPD, diabetes, antibacterials, antifungals, cystic fibrosis, growth factors, cardiovascular disease, hormone replacement therapy, and lung cancer. He has been responsible for the preclinical portions of approved pulmonary drugs and excipients including QVARTM, Proventil-HFATM, HFA-134a, and HFA-227. He has prepared numerous INDs and NDAs and has registered drugs in over 50 countries.
Dr. Leach has held positions at Eli Lilly, IIT Research Institute, Battelle Memorial Institute, 3M Pharmaceuticals and Nektar Therapeutics (formerly Inhale Therapeutics) prior to joining Lovelace. He is a member of the American Thoracic Society, the American Association of Pharmaceutical Scientists, the International Society for Aerosols in Medicine, the American Association of Pharmaceutical Scientists, American Diabetes Association and the Society of Toxicology.
Dr. Leach has a B.S. degree in mathematics, an M.S. in organic chemistry, and a Ph.D. in pulmonary toxicology. He is board certified by the American Board of Toxicology. He has over 100 manuscripts, abstracts, book chapters and patents in the pulmonary arena.